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Chlamydia trachomatis, an obligate intracellular bacterium, is a highly prevalent human pathogen.
Hydroxamic-acid-based matrix metalloprotease inhibitors can effectively inhibit the pathogen both
in vitro and in vivo, and have exhibited therapeutic potential. Here, we provide genome
sequencing data indicating that peptide deformylase (PDF) is the sole target of the inhibitors in
this organism. We further report molecular mechanisms that control chlamydial PDF (cPDF)
expression and inhibition efficiency. In particular, we identify the s
66-dependent promoter that
controls cPDF gene expression and demonstrate that point mutations in this promoter lead to
resistance by increasing cPDF transcription. Furthermore, we show that substitution of two amino
acids near the active site of the enzyme alters enzyme kinetics and protein stability.
INTRODUCTION
Chlamydia trachomatis is one of two species of chlamydiae
that naturally infect humans, and is arguably the number
one sexually transmitted bacterial pathogen worldwide
(Schachter, 1999). Sexually transmitted chlamydial infec-
tion may lead to cervicitis, endometritis and salpingitis in
women, and urethritis and lymphogranuloma venereum in
both men and women. In addition, some serovars are
responsible for preventable blindness in developing coun-
tries (Schachter, 1999).
Chlamydiae havea unique developmentalcycle that involves
two cellular forms. The metabolically quiescent, infectious
elementary body (EB) is taken into a vacuole designated an
inclusion through host cell endocytosis. Inside the inclusion,
the EB develops into the proliferative but non-infectious
reticulate body (RB). As RBs accumulate, they differentiate
back into EBs in an asynchronous manner (Moulder, 1991).
At the end of the developmental cycle, EBs and residual RBs
are released when the infected cell bursts.
In an attempt to investigate the mechanisms underlying
chlamydial development, we assessed the effects of small
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host mammalian cells. This screen identified hydroxamate-
based matrix/ecto-metalloprotease inhibitors, exemplified
by N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpen-
tanoyl]-L-tryptophan methylamide, designated GM6001,
and N-(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methyl-
pentanoyl-L-naphthylalanyl-L-alanine amide, known as
TAPI, as highly effective inhibitors of C. trachomatis infec-
tion without detectable toxicity to host cells (Balakrishnan
et al., 2006, 2009). Time kinetics revealed that the com-
pounds do not inhibit chlamydial entry into the host cell.
Therefore, the inhibitors might directly target a chlamydial
gene product that is essential for chlamydial infection;
alternatively, the activity of a host metalloprotease or another
hydroxamate-inhibited host metalloenzyme may indirectly
support chlamydial growth. Interestingly, whereas a point
mutation has been identified in a 59-non-coding region of the
peptide deformylase (PDF) gene in a chlamydial variant
designated GR10 that was selected to grow in the presence of
GM6001, no mutations were found in the variant’s
metalloprotease genes (Balakrishnan et al., 2006).
PDF is a metallohydrolase essential for protein maturation
in lower organisms. Newly synthesized proteins in eubac-
teria are led by N-formylmethionine. In most cases, bacterial
neopeptides are converted to mature proteins through the
sequential removals of the N-formyl group and methionine
by PDF and methionine aminopeptidase, respectively. In a
small proportion of proteins, the initiator methionine is
retained after the removal of the formyl group (Capecchi,
1966). Similar to the zinc-dependent matrix metallopro-
teases, PDF contains a metal-binding HEXXH (X, any
amino acid) motif. Based on studies of PDFs from a limited
number of species, it is generally thought that the enzyme
uses ferriciron in vivo forcatalysis(Rajagopalan et al., 1997).
However, recombinant PDFs with other divalent metal ions,
cobalt, nickel and zinc, in place of iron can be prepared,
although metal substitution may affect enzyme activity
(Rajagopalan et al., 1997); furthermore, a PDF using zinc as
the native catalytic ion has been identified in an iron-
deficient bacterium (Nguyen et al., 2007). In addition to the
correlation of the chlamydial PDF (cPDF) gene mutation
with the GM6001-resistant phenotype, and the absence
of any metalloprotease gene mutation, there was also
an increased cPDF protein level in GR10. Furthermore,
GM6001 and TAPI directly inhibited cPDF enzyme activity
(Balakrishnan et al., 2006). These findings prompted us to
hypothesize that these compounds interfere with C.
trachomatis growth by exclusively targeting cPDF.
Deletion of the PDF gene in Escherichia coli results in a
lethal phenotype (Mazel et al., 1994), indicating that PDF is
a potential antibacterial target. Consistent with this notion,
topical application of GM6001 significantly reduced the
loading of Chlamydia muridarum, a mouse pathogen that
models human chlamydial diseases, in mice that were
vaginally infected (Balakrishnan et al., 2009). In addition,
other peptide deformylase inhibitors have been shown to
inhibit chlamydiae in vitro (Apfel et al., 2000; Wise et al.,
2002). The therapeutic and prophylactic potential of
GM6001 and related compounds implicated by these
findings highlights the necessity to determine whether they
solely target cPDF and how the activity of this essential
enzyme is regulated in Chlamydia, since answers to these
questions are important for the design of new inhibitors
with potential therapeutic value. Due to the lack of a
methodology for gene transfer, we tested the single-target
hypothesis by sequencing the whole genome of GR10, and
investigated the mechanisms that regulate cPDF activity
and inhibition efficiency by isolating additional resistant
mutants. Our work concludes unambiguously that GM6001
and TAPI exclusively target cPDF in this pathogen. We also
show that mutations in the 59-non-coding region of the
cPDF gene cause resistance to the inhibitors by elevating
cPDF gene transcription through distinct mechanisms.
Finally, we demonstrate that amino acid changes near the
active site of the cPDF protein can lead to resistance by
altering enzymic properties and protein stability.
METHODS
Reagents. GM6001 was purchased from Calbiochem. N-Formyl-
methionine-alanine-serine (fMAS) was purchased from Bachem
Biosciences. Total RNA isolation (TRI) reagent was purchased from
Sigma-Aldrich Chemicals. The TALON metal affinity resin was
purchased from Clontech. The enhanced chemiluminescence (ECL)
and ECL Plus kits were purchased from Amersham. 2,4,6-
Trinitrobenzenesulfonic acid (TNBSA) was purchased from Pierce.
Taqman reverse transcription kit and SYBR Green PCR Core kit were
purchased from Applied Biosystems. E. coli RNA polymerase
holoenzyme saturated with s
70 (eRNAP) and the core enzyme lacking
any s factor (eCore) were purchased from EPICENTRE. eRNAP
lacking the C-terminal domain of the a subunit (DCTD) was purified
using a novel method that enables isolation of in-vivo-assembled,
recombinant eRNAP holoenzyme lacking amino acid residues 236–
329 of the a subunit (Twist et al., 2011). Monoclonal antibodies
against chlamydial major outer-membrane protein (MOMP) and
lipopolysaccharide (LPS) (Greene et al., 2004; Xiao et al., 2004) and a
polyclonal mouse anti-cPDF (Balakrishnan et al., 2006) have been
described previously and were generous gifts from Dr Guangming
Zhong (University of Texas Health Sciences Center at San Antonio).
Strains and culture conditions. C. trachomatis serovar L2 (L2,
strain 434/bu) was purchased from the American Type Culture
Collection (ATCC) and expanded using HeLa cells as the host
(Balakrishnan et al., 2006). GR10 is an L2 variant that was selected for
resistance to GM6001 as we reported previously (Balakrishnan et al.,
2006). Selection of Z1 was carried out with essentially the same
procedures as for that of GR10 except that an ethyl methanesulfonate-
mutagenized L2 stock was used as a starting material. Detection of
chlamydial inclusions and determination of EB titres were done as
detailed previously (Balakrishnan et al., 2006). ArcticExpress E. coli
was purchased from Stratagene. E. coli BW25113 substrains carrying
wild-type or mutated cPDF alleles in place of the bacterial
endogenous PDF gene (i.e. PDF-replacement E. coli) were constructed
with phage l Red recombinase technology (Datsenko & Wanner,
2000). Luria–Bertani (LB) medium (broth and 1.2% agar plates) was
used to culture E. coli. The MIC of GM6001 for E. coli was determined
by inoculating exponential-phase bacteria on agar plates (8000
bacteria per plate) containing 1:2 serially diluted inhibitor and
culturing the plates at 37 uC for 48 h.
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chlamydial stocks at three multiplicities of infection. At 24 h after
infection, total cellular and chlamydial RNA was extracted with the
TRI reagent following the manufacturer’s instructions and treated
twice with RNase-free DNase (Akers & Tan, 2006). To ensure that the
RNA preparations were free of genomic DNA contamination, PCRs
were performed to test whether MOMP and cPDF gene fragments
could be amplified directly from the RNA. While reactions using 1 ng
control genomic DNA showed amplification of expected DNA bands,
those with 10 mg RNA samples prepared with double DNase
digestions did not, confirming complete removal of genomic DNA
from the RNA preparations.
cDNA preparation. MOMP and cPDF cDNAs were synthesized by
using gene-specific primers (MOMP, 59-CAGCTGCGTTACAGAGAA-
39; cPDF, 59-CATGCATTACAATGCTTGCTA-39) and the Taqman
Reverse Transcription kit, following the manufacturer’s instructions.
Quantitative PCR (qPCR). qPCR was performed on an Opticon
real-time PCR machine (MJ Research) using the SYBR Green PCR
Core kit. The 59 primers for cPDF and the reference MOMP gene were
59-GAGGTAGCTAGACCCGATAAG-39 and 59-GAGTGCTGGAGC-
TCGTGC-39, respectively. The 39 primers were the same as those for
cDNA synthesis described above.
Western blotting. Chlamydia-infected HeLa cells were lysed in SDS-
PAGE gel loading buffer at 24 h after infection. PDF-replacement E.
coli cultured in LB broth was harvested in the same buffer when the
OD600 reached 0.8. The extracts were further sonicated. MOMP and
cPDF were detected by ECL and ECL Plus, respectively. The signal
intensities of the protein bands were quantified by densitometry
(Balakrishnan et al., 2006).
Preparation of crude genomic DNA for PCR and Sanger
sequencing. Chlamydiae were released from cells 40 h after infection
by replacing the culture medium with water and incubating at room
temperature for 10 min. Following centrifugation (500 g, 15 min) to
remove cell debris, chlamydiae were lysed in buffer containing SDS
and Triton X-100, and subjected to overnight digestion with
proteinase K (Balakrishnan et al., 2006). Nucleic acids were purified
by phenol/chloroform extraction.
Sequencing of the cPDF gene. Primers for amplifying and
sequencing the cPDF gene as well as a portion of each of the
neighbouring CTL0606 (corresponding to CT352 of C. trachomatis
D) and CTL0608 (corresponding to CT354) have been reported
(Balakrishnan et al., 2006). The DNA fragment was PCR-amplified,
gel-purified and subjected to automated sequencing based on
fluorochrome-conjugated dideoxynucleotide termination. The amp-
lification primers were used for sequencing.
Preparation of highly purified chlamydial genomic DNA for
whole genome sequencing. HeLa cells were infected with GR10.
Chlamydiae were released from infected cells as described above. Host
DNA and RNA were removed by incubating the lysates at 37 uC for
30 min after the addition of DNase and RNase. EBs in the lysates were
purified by ultracentrifugation through 40%/44%/52% Renocal
gradients (Caldwell et al., 1981). Nucleic acids were extracted as
described above. Highly purified chlamydial DNA was obtained
following RNase digestion, phenol/chloroform extraction and ethanol
precipitation.
Full genome sequencing. Genome sequencing, including library
preparation, Solexa cluster generation and single-end-read sequen-
cing, was performed by Creative Biolabs.
Production of His-tagged cPDF. pET21-based vectors for expres-
sing F134C, R137S and F134C/R137S cPDF carrying a carboxyl-
terminal His6-tag were constructed similarly to that for wild-type
cPDF as previously described (Balakrishnan et al., 2006). Production
and purification of the recombinant proteins were carried out
following published procedures with modification (Balakrishnan et
al., 2006). Briefly, plasmid-transformed ArcticExpress E. coli was
cultured on a shaker at 30 uC. When the OD600 of the culture reached
~0.8, the culture temperature was lowered to 13 uC. IPTG was added
to the culture (final concentration: 1 mM) to induce recombinant
gene expression. After overnight culture at 13 uC, the bacteria were
collected by centrifugation and lysed by a French press. Cell debris
was removed by centrifugation at 25000 g for 30 min. cPDFs were
purified with the TALON affinity metal resin and were stored at
280 uC after the addition of glycerol to a final concentration of 10%
(v/v).
cPDF activity assay. An assay previously developed for the E. coli
PDF (Groche et al., 1998) was modified to measure the activity of the
chlamydial enzyme. The assay mix, in a total of 50 ml reaction
volume, contained 50 mM HEPES (pH 7.2), 10 mM NaCl, 125 ng
cPDF, 0–50 mM fMAS and 50–500 nM GM6001. The deformylation
reaction was allowed to proceed at 37 uC for 10 min and then
terminated by heating at 95 uC for 2 min. The amount of MAS
produced was reported by TNBSA, which reacts with the free amine
group to form a chromogenic peptide conjugate. Briefly, 550 ml
0.0036% TNBSA, freshly prepared in 0.1 M NaHCO3, was added to
the reaction and incubated at 37 uC for 1 h. Following the addition
of 200 ml 10% SDS and 100 ml 1.0 M HCl, the peptide–TNBSA
conjugate was quantified by measuring A335. All A335 values were
within the range of free methionine standards. Catalytic constants
were calculated from Lineweaver–Burk plots. Data presented were
calculated from three experiments, except the Ki for the F134C/R137S
cPDF, which was calculated from two experiments.
Preparation of chlamydial RNA polymerase (cRNAP). cRNAP
was prepared from L2-infected suspension culture of mouse L cells
using heparin-conjugated agarose as previously described (Tan &
Engel, 1996).
Preparation of recombinant chlamydial s
66. The ORF of s
66 of L2
was cloned into the pET28 vector, designed for expression of amino-
terminally His-tagged proteins using NdeI and XhoI cutting sites.
Expression of the recombinant s
66 in E. coli and purification using the
TALON affinity metal resin were carried out as described for His-
tagged cPDF.
In vitro transcription assay. The abilities of DNA fragments
containing candidate promoter sequences to direct RNA synthesis
were determined using an in vitro transcription assay previously
described (Tan & Engel, 1996). Briefly, the fragments were cloned
into the transcription vector pMT1125 (Yu et al., 2006) between the
XbaI and EcoRV cutting sites. Immediately downstream of the EcoRV
site in pMT1125 is a 154 bp G-less transcription cassette (Yu et al.,
2006). The assay in a total volume of 30 ml contained 300 ng
supercoiled plasmid DNA, 1 mM potassium acetate, 8.1 mM
magnesium acetate, 50 mM Tris/acetate (pH 8.0), 27 mM ammo-
nium acetate, 1 mM dithiothreitol, 3.5% (v/v) polyethylene glycol
(average molecular mass, 8000), 330 mM ATP, 330 mM UTP, 1 mM
CTP, 0.21 mM [a-
32P]CTP [3000 Ci mmol
21 (111 TBq mmol
21,
100 mM3 9-O-methyl-GTP, 36 units of RNasin and RNA polymerase
[i.e. cRNAP, eRNAP (E. coli RNAP holoenzyme) or eCore (E. coli
RNAP core enzyme free of s
70) plus recombinant chlamydial s
66].
The reaction was allowed to proceed at 37 uC for 30 min and
terminated by the addition of 70 ml 2.86 M ammonium acetate
containing 4 mg glycogen. After ethanol precipitation,
32P-labelled
RNA was resolved by urea-PAGE and visualized on a Storm
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157 nt transcript bands were determined by the ImageQuant
software. Data presented in bar graphs are means±SD of three
experiments.
RESULTS
The cPDF gene is the only gene mutated in the
chlamydial variant GR10
The identification of a point mutation in the cPDF gene in
strain GR10, selected for resistance to GM6001 and TAPI,
suggests that these compounds target cPDF even though
they are best known as metalloprotease inhibitors
(Balakrishnan et al., 2006). Nevertheless, the lack of a
genetic system to conveniently manipulate C. trachomatis
makes it difficult to rule out the possibility that they may
have an additional target in this organism. To address this
concern, the whole genome of GR10 was sequenced using
the Solexa platform (Bennett, 2004). The genome resequen-
cing project generated a total of 7825806 reads. Among
these, 7450375 reads were matched to the reference L2
genome (Thomson et al., 2008), whereas the remaining
375431 (4.8% of the total) reads represented contaminating
DNA sequences from the host cells. The average coverage
depth was 2566, leaving no unsequenced gap in the
1038842 bp genome (Thomson et al., 2008). As expected,
Solexa sequencing identified the known CAA mutation in
the 59-non-coding region of the cPDF gene, corresponding
to nucleotide 723246 in the reference genome (Thomson
et al., 2008). No additional mutations were found in the
GR10genome.Thus,cPDFis theauthenticandsole targetof
GM6001 and TAPI in chlamydiae. Furthermore, we
performed qPCR analysis using primers targeting the
cPDF and the MOMP genes to determine if the mutated
cPDF genehadundergoneamplification inGR10.Thesignal
ratios of cPDF:MOMP were the same between GR10 and
wild-type L2 (data not shown). Since these two genes are
~350 kb away from each other, the probability for the two
genes to have coamplified is very low. Thus, qPCR
eliminated the possibility of PDF gene amplification as a
mechanism for resistance to PDF inhibitors, which had been
observed in Haemophilus influenzae (Dean et al., 2007).
CAA mutation in GR10 increases cPDF gene
transcription
The mutation in GR10 is located 245 nt upstream of the
ATG initiation codon of the cPDF ORF and 7 nt
downstream of the Rho-independent transcription ter-
mination signal of the neighbouring CTL0608 gene (Fig.
1a; see also Supplementary Table S1, available with the
online version of this paper), suggesting that the mutation
confers GM6001/TAPI resistance by increasing the cPDF
gene expression. To test this hypothesis, we set out to
identify the transcription initiation site in the gene. 59-
Rapid amplification of cDNA ends (RACE) using the
39GSP2 primer (see Supplementary Table S2) yielded two
cDNA end fragments, designated CEF1 and CEF2 (Fig.
1a,b; Supplementary Table S1). Sequencing analyses
revealed that CEF1 started at 40 or 41 nt downstream of
the mutation site of GR10, and CEF2 began at 137 or
138 nt downstream (Fig. 1c; Supplementary Table S1).
Between the mutation and the CEF1 initiation site there is
a fragment with the sequence TTTCCA-(n)17-CACAAT
(Fig. 1a) that loosely resembles the consensus s
66 promoter
sequence, TTGACA-(n)~17-TATAAT (Tan, 2007). In con-
trast, no apparent promoter elements are readily recog-
nized in the fragment upstream of the CEF2 initiation site.
Since many chlamydial genes do not have consensus
promoter elements (Tan, 2007), we used in vitro tran-
scription assays to determine whether either or both
upstream DNA fragments have promoter activity. While
both the commercial eRNAP and cRNAP, purified from
RBs, directed the synthesis of a reporting G-less RNA
product from the candidate promoter fragment PF1, a
genomic DNA fragment upstream of CEF1, neither RNAP
synthesized RNA from the expanded promoter fragment
PF2, which contained the additional 137 nt upstream of
CEF2 (Fig. 1d and Supplementary Table S1). As expected,
no transcriptional product was detected from the control
promoter-less vector using either RNA polymerase. These
results suggest that the smaller cPDF mRNA fragment that
gave rise to CEF2 in 59-RACE is a degradation intermediate
of the full-length cPDF mRNA.
To determine if CEF1 might also correspond to a
degradation intermediate of the cPDF mRNA, we
attempted to amplify cPDF cDNA from the whole cDNA
preparation using two alternative 59-primers. One of these,
Lt2-59, targeted the 59-end of CEF1, while the other, Lt1-59,
targeted a sequence immediately upstream of the 59 end of
CEF1 (Fig. 1a; Supplementary Table S1). Use of either Lt2-
59 or Lt1-59 in conjunction with the 39-primer 39GSP2
amplified the expected 443 bp or 460 bp fragments when
genomic DNA was used as template. In contrast, when
cDNA was used as a template use of Lt2-59 in conjunction
with 39GSP2 amplified the expected 443 bp product (Fig.
1e) whereas use of Lt1-59 in conjunction with 39GSP2 did
not generate a product (Fig. 1e), suggesting that CEF1 is
not a degradation intermediate. Taken together, the data
presented in Fig. 1 indicate that the cPDF gene transcrip-
tion is initiated at 40 or 41 nt downstream of the CAA
mutation in GR10. This transcription start site is 5 nt
earlier than the one reported in a transcriptome study
using deep RNA sequencing (Amero et al., 2009).
Next, we determined the effect of the GR10 mutation on
transcription. To do this, we compared the yields of
transcripts generated in vitro in reactions performed using
either the wild-type PF1 template or a template carrying
the GR10 mutation. We found that introduction of the
GR10 mutation into the PF1 template resulted in a 2.8-
and 2.4-fold increase in yields of full-length transcripts, in
reactions done with eRNAP (Fig. 2a, left) and cRNAP
(Fig. 2a, middle), respectively. A 3.1-fold increase in
X. Bao and others
2572 Microbiology 157Fig. 1. The GR 10 mutation was mapped to 40 nt upstream of the cPDF gene transcription start site. (a) Schematic drawing of the
59-non-coding region of the cPDF gene, the 39-end of the neighbouring CT0608 gene and locations of primers used for 59-RACE
andtheconfirmationoftranscriptionstartsite.SeeTableS1forpositionsofthegenesandrelatedfragmentsinthegenomeaswellas
the sizes of the fragments, and Table S2 for details of primers used. The stop sign signifies the Rho-independent transcription
terminationsignal of CTL0608. Notethat thefragmentsizesarenotto scale, andthe gene fragment ofCTL0608 is shown in halftone.
The position of the CAA mutation in GR10 relative to the translation initiation site and the transcription start site as determined in
panels (b–e) are numbered with and without parentheses, respectively. Putative ”35 and ”10 promoter elements are boxed and the
UP element underlined. (b) Two cDNA 59-end fragments, CEF1 and CEF2, corresponding to fragments in the cPDF gene drawn in
(a), were detected by 59-RACE using the primer 39GSP2. In the left lane are 100 bp DNA markers; the lowest band is 100 bp. The
indicated fragment sizesdo not include the extraG:C pairs attached by the 59-RACE reaction. (c) Sequencing trace forms showing
59-ends of CEF1 and CEF2. Bidirectional arrows point to the 59-end of the cDNAs. (d) In vitro RNA synthesis directed from the PF1
promoter fragment, which ends upstream of the 59-end of CEF1, but not from PF2, which ends upstream of CEF2. Arrows point to
the 157 nt transcript. See (a) for locations of PF1 and PF2 in the genomic DNA and Table S1 for details of primers (P59-Xba, P1-39
and P2-39) used to clone PF1 and PF2 into pMT1125 (Yu et al., 2006). (e) Amplification of cPDF cDNA using a 59-end primer (Lt2)
with sequence corresponding to the end of CEF1, but not a primer (Lt1) with sequence immediately upstream of the CEF1. The 39
primer for all PCRs was 39GSP2 (Table S2). Genomic DNA (gDNA) was used as control. Left lane: molecular markers as in (b).
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70-free eCore in
the presence of recombinant chlamydial s
66 (Fig. 2a,
right). Consistent with these in vitro transcription data,
reverse transcriptase qPCR analysis detected a 5.5-fold
increase in the abundance of cPDF mRNA, relative to the
mRNA level of MOMP, in GR10, as compared with wild-
type L2, at 24 h after infection (Fig. 2b), which is
consistent with our previous analysis demonstrating a
comparable degree of elevation in the level of cPDF
protein (Balakrishnan et al., 2006).
In addition to the recognition of the 235 and 210
promoter elements by s
66, promoter binding also involves
interactions between the C-terminal domain of the RNAP
a subunit (aCTD) and sequences immediately upstream
of the promoter 235 element (Haugen et al., 2008).
Furthermore, at certain promoters (most notably the
ribosomal promoters) the aCTD makes sequence-specific
contact with an A+T-rich sequence element, called the UP
element. Given that the GR10 mutation increases the A+T
content of the DNA upstream of the putative 235 hexamer
(Fig. 1a), we hypothesized that the GR10 mutation increases
transcription from the cPDF promoter by stabilizing
interactions between the aCTD and upstream DNA. To test
this hypothesis we performed in vitro transcription reactions
using RNAP lacking the aCTD. In this case, yields of full-
length transcripts were essentially identical in reactions
performed using the wild-type template or reactions
performed using the template carrying the GR10 mutation
(Fig. 2c). These findings are consistent with the hypothesis
that the GR10 mutation increases transcription from the
cPDF promoter by stabilizing interactions between the
aCTD and upstream DNA.
Identification of four point mutations in the cPDF
gene of resistant variant Z1
GM6001 not only inhibits chlamydial growth in cell
culture, but also can reduce vaginal chlamydial loading in
a mousemodel(Balakrishnanetal.,2009).Thissuggests that
PDF inhibitors may be useful for prevention and treatment
of chlamydial infection. Therefore, we sought to identify
additional mechanisms that control cPDF activity, as such
investigation may help the design of cPDF-targeting drugs.
We approached this by selecting and characterizing new
GM6001-resistant mutants. To increase the efficiency of
mutant selection, we performed random mutagenesis using
the DNA-damaging reagent ethyl methanesulfonate. From a
mutagenized L2 stock, we obtained a GM6001-resistant
mutant designated Z1. Compared with GR10, Z1 exhibited
an even stronger tolerance to GM6001, as indicated by
immunofluorescence microscopy detecting chlamydial
inclusions formed in the presence of GM6001 (Fig. 3a)
and by the enumeration of progeny EBs produced by
GM6001-treated cultures (Fig. 3b).
A 1142 bp genomic DNA fragment that covers the entire
cPDF gene (i.e. CTL0607, coding and non-coding regions)
Fig. 2. The non-coding nucleotide mutation in GR10 increases cPDF gene transcription by stabilizing promoter–aCTD
interactions. (a) Promoter fragment containing the GR10 mutation showed increased transcription activity, as compared with
the wild-type promoter fragment, in in vitro transcription assays using either E. coli RNAP holoenzyme (eRNAP), chlamydial
RNAP (cRNAP) or the hybrid eCore/s
66 holoenzyme made of the E. coli RNAP core enzyme (eCore) and recombinant
chlamydial s
66. Bands and quantitative data of the 154 nt
32P-labelled report transcript are shown. (b) Overexpression of the
cPDF mRNA in GR10 as demonstrated by qPCR. (c) The GR10 mutation failed to stimulate transcription in vitro using eRNAP
lacking the aCTD (DCTD). Data represent means±SD of three or more experiments.
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neighbouring genes (i.e. CTL0606 and CTL0608) of the Z1
variant was sequenced, which revealed four point muta-
tions in the cPDF gene (Fig. 3c). Two of the mutations
were found in the 59-non-coding region, one at nucleotide
231 relative to the transcription start site and the other at
210 relative to the translation initiation codon. The
remaining two point mutations were found in the coding
region, leading to two amino acid substitutions (F134C
and R137S) in the protein.
A putative ”35 promoter element mutation
increases cPDF transcription
The locations of the mutations suggest that a number of
mechanisms contribute to the resistance in Z1. First, the
most upstream mutation may increase transcription by
enhancing the s
66 binding since the mutation lies in the
putative 235 promoter element and the new TTTACA
hexamer in Z1 is predicted to be a more favourable
hexamer for s
66 as compared with the wild-type TTTCCA
sequence, based on findings from an in vitro mutational
analysis of the dnaK promoter (Schaumburg & Tan, 2003).
For the convenience of description, this mutation is
designated Z1P235. Second, since the mutation near the
translation start site is in the ribosomal binding site (RBS)
in mRNA, it might increase protein translation efficiency.
Indeed, a similar mutation has previously been reported to
be responsible for the overexpression of ribonucleotide
reductase small subunit and thus for increased resistance to
hydroxyurea, an inhibitor of the reductase, in C. tracho-
matis (Roshick et al., 2000). Third, since F134 and R137 are
near the essential metal-binding HEXXH motif of cPDF
(Fig. 3c), the F134C and R137S substitutions probably alter
the enzyme activity.
We performed in vitro transcription to test the hypothesis
that the Z1P235 mutation increases the cPDF gene
transcription. Both cRNAP and eRNAP synthesized higher
levels of full-length transcripts from PF1 harbouring the
mutation, as compared with the wild-type PF1 (Fig. 4a).
Consistent with the in vitro transcription data, reverse
Fig. 3. Resistance to GM6001 and cPDF gene mutations in the Z1 variant. (a, b) HeLa cell monolayers were infected with an
EB stock of wild-type C. trachomatis, GR10 or Z1 and were cultured with medium containing the indicated concentrations of
GM6001. (a) Immunofluorescence microscopy was performed 24 h after infection using the anti-LPS antibody and a FITC-
conjugated secondary antibody to visualize inclusions (green). DAPI was used to counterstain DNA (blue). Experiments were
done twice and yielded similar results. (b) Progeny EB production (means±SD of two experiments) was determined 40 h after
infection by quantifying inclusions formed in secondary cultures. (c) Schematic presentation of four mutations in the cPDF gene
of Z1. Mutated nucleotides and amino acids in Z1 as well as their wild-type counterparts are shown in colour. Putative ”35 and
”10 promoter elements are shown in boxes. Amino acids are numbered in parentheses. The leading methionine and metal-
binding HEXXH motif are underlined.
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the cPDF mRNA in the Z1 mutant (Fig. 4b); furthermore,
Western blotting revealed a similar increase in the level of
cPDF protein (Fig. 4c).
Since the Z1P235 mutation is located in the putative 235
hexamer, which binds s
66, we hypothesized that the ability
of the mutation to increase transcription is not affected by
the deletion of the aCTD. Indeed, the Z1P235 mutation
also increased levels of full-length transcripts in reactions
performed with DCTD (Fig. 4d). As the aCTD-less
polymerase failed to produce an increased amount of
full-length transcripts from the PF1 template carrying the
GR10 mutation (Figs 2c and 4d), the GR10 and Z1P235
mutations upregulate cPDF gene transcription through
distinct mechanisms.
F134C and R137S substitutions and non-coding
mutations contribute to resistance
We next determined the roles of F134C and/or R137S in
resistance. The lack of a method to genetically manipulate
C. trachomatis made it impossible to directly assess the
role of each of the mutated residue in the resistance. To
circumvent this technical difficulty, we set out to
construct E. coli bearing the ORF of wild-type, F134C,
R137S or the F134C/R137S cPDF in place of the
endogenous PDF ORF using the phage l Red recombinase
methodology (Datsenko & Wanner, 2000). We obtained
multiple E. coli clones with F134C, R137S or wild-type
ORF replacement after a single round of engineering. PCR
was performed using primers targeting the flanking
sequences of the E. coli PDF ORF to confirm the
replacement (data not shown). However, we were unable
to construct replacement E. coli bearing the F134C/R137S
ORF despite multiple attempts. The abilities of the F134C
and R137S replacement bacteria (three clones each) to
grow in the presence of GM6001 were determined.
Consistent with a previous report from our lab, E. coli is
intrinsically much more resistant to GM6001 than
chlamydiae (Balakrishnan et al., 2006): the MIC of
GM6001 is at millimolar level in the enterobacterium
and in the micromolar range in chlamydiae. Nevertheless,
the effects of different cPDFs on the tolerance to GM6001
in E. coli were evident on agar plates. Thus, whereas
bacteria expressing the F134C cPDF resisted a fourfold
higher GM6001 concentration as compared with the
bacteria expressing wild-type cPDF, those expressing the
R137S cPDF also exhibited a twofold higher tolerance
(Fig. 5a). Furthermore, growth curves established in liquid
medium containing 0.25 mM GM6001, which is below the
MICs, also showed higher levels of resistance to GM6001
in the F134C and R137S replacement E. coli (Fig. 5b).
Our failure to replace the ORF of the endogenous PDF of
E. coli with that of the F134C/R137S cPDF suggests that the
mutant chlamydial enzyme is unable to replace the
endogenous E. coli PDF. Nevertheless, when the 59 non-
coding region containing the Z1P235 and the RBS
mutation from Z1 was included in the targeting allele, we
readily obtained replacement bacteria, as confirmed by
genomic PCR analysis (data not shown). The MICs of
Fig. 4. The Z1P”35 mutation increases transcription from the cPDF promoter. (a) Transcription from PF1 (Fig. 1) harbouring the
Z1P”35 mutation or GR10 mutation was increased, as compared with that from wild-type PF1, using cRNAP or eRNAP. (b, c)
Increased cPDF mRNA and protein, respectively, were detected in Z1 as compared with wild-type C. trachomatis. (d) The
transcription-stimulatory activity of the Z1P”35 mutation but not the GR10 mutation was detectable using DCTD. Experiments
in (a–d) were performed as in Fig. 1. Data represent means±SD of three or more experiments.
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the quadruple mutations were 8 mM, whereas those for
the three replacement clones carrying the 59 non-coding
region and the ORF of wild-type cPDF were 1 mM. These
data further illustrate the roles of the 59 non-coding
mutations in cPDF overexpression and GM6001 resistance
in Z1 (Fig. 5c).
Changes in kinetic properties in F134C, R137S
and F134C/R137S cPDFs
To assess the effects of F134C and R137S substitutions on
enzyme properties, we expressed cPDF with either or both
substitutions as well as wild-type cPDF protein in E. coli
and purified them to near homogeneity (data not shown).
With fMAS as a substrate, the F134C and R137S single
mutants both had a nearly twofold higher Km as compared
with the wild-type enzyme, whereas the double mutants
had a nearly 10-fold larger Km (Table 1). All the mutant
enzymes had increased kcat values over the wild-type
enzyme (Table 1). The two single mutants exhibited
increased kcat/Km values whereas the double mutant has a
significant 27% decrease in the kcat/Km value, as compared
with that of wild-type (Table 1). The Ki of GM6001 for the
F134C/R137S cPDF variant was 6.3-fold higher than that
for wild-type (Table 1). In comparison, the two single
cPDF mutants had Ki values similar to the wild-type
enzyme (Table 1).
F134C and R137S mutations affect cPDF protein
stability
As shown in Fig. 5, the two singly mutated PDF proteins
exhibited very similar (if not identical) enzymic kinetics.
However, in gene targeting experiment, the F134C cPDF
conferred a twofold higher resistance to GM6001 than the
R137S form in E. coli. To resolve this discrepancy, we
determined the expression levels of the two mutants in
bacteria by Western blot analyses. Interestingly, the
expression level of F134C cPDF is higher than that of the
wild-type protein, while that of the R137S is lower (Fig.
6a). A duplicate gel, stained with Coomassie blue, showed
equal amounts of protein loadings among the replacement
mutants (Fig. 6a, bottom). Western blotting analysis
showed that the cPDF antibody recognized the two forms
of purified His-tagged cPDF proteins equally efficiently
(data not shown).
Analyses were performed to probe possible mechanisms
leading to the variation in protein expression of the F134C
and R137S cPDFs. First, the promoter region of the ORF
replacement E. coli was sequenced, and no mutation was
detected. Second, the amounts of cPDF mRNA relative to
the 10S rRNA in the three ORF replacement bacteria were
determined and found to be comparable (Fig. 6b). As
expected, there was a large increase of cPDF mRNA in
replacement E. coli carrying both the ORF and 59 non-
coding region of the cPDF of Z1, compared with the
Fig. 5. Effects of F134C, R137S and non-coding mutations found in Z1 on GM6001 resistance in E. coli. (a) PDF replacement
E. coli clones carrying the ORF for the F134C or the R137S cPDF displayed increased MICs as compared with wild-type ORF-
replacement clones. MIC was determined on agar culture plates with 1:2 serially diluted GM6001. (b) F134C and R137S
ORF-replacement E. coli exhibited high levels of resistance to 0.25 mM GM6001 in liquid culture medium as compared with
wild-type ORF-replacement bacteria. Growth was assessed by OD600. Data are means±SD of three experiments. (c)
Concurrent replacement of the Z1 mutant’s ORF and 59 non-coding sequence (59NC) in E. coli resulted in an increased MIC for
the inhibitor. In (a) and (c), for each replacement, three clones were analysed and had the same MIC.
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sequences (Fig. 6c). Taken together, these results suggest
that F134C and R137S substitutions affect cPDF protein
stability.
DISCUSSION
Although C. trachomatis is susceptible to a number of
antibiotics, the majority of infected individuals do not seek
medical treatment. This is true even in places with good
health care because the infection often generates very mild
or no symptoms (Schachter, 1999). Without proper
antibiotic treatment, more than one-third of infected cases
develop serious complications, including infertility, ectopic
pregnancy, abortion and chronic pelvic inflammatory pain
syndrome (Schachter, 1999). Infected people are also at
increased risk of HIV acquisition, due to ulcerative damage
caused by C. trachomatis replication (Stamm et al., 1988).
Therefore, identification of potential new therapeutic and
prophylactic targets in this organism is of high importance.
Our previous study on GR10 suggested that inhibition of
cPDF rather than metalloproteases of either host or
parasitic origin accounts for the antichlamydial effect of
GM6001 (Balakrishnan et al., 2006). Nevertheless, that
study did not rule out the possibility that the inhibitor has
another target in Chlamydia. In this work, full genome
sequencing revealed the cPDF gene as the only gene
carrying a mutation in GR10. The discovery of cPDF as the
exclusive target of GM6001 in Chlamydia is of significance
for the development of GM6001 derivatives for the
treatment and prevention of chlamydial disease, and
further raises the importance of understanding the
regulation of cPDF activity.
The chlamydial genome encodes three s factors: the
primary s factor s
66 and the alternative s factors s
28 and
s
54 (Stephens et al., 1998). Our findings suggest that the
cPDF gene is recognized by s
66. Thus, our cRNAP, which
should contain only s
66 but not the two alternative s
factors according to previous studies (Tan, 2007), can
Table 1. Changes in catalytic constants in cPDF loop mutants
Data are means±SD.
Catalytic constant Wild-type F134C R137S F134C/R137S
Km for fMAS (mM) 5.0±0.6 9.2±0.5** 9.3±1.1** 48.0±1.9**
% of control 100 184 186 965
kcat (s
21) 6.4±0.5 19.6±2.0** 22.1±2.1** 45.3±4.2**
% of control 100 306 344 705
kcat/Km (M
21 s
21) 1296±79 2143±215** 2387±85** 948±124*
% of control 100 165 184 73
Ki for GM6001 (nM) 160±35 143±0.1 148±41 1000±11**
% of control 100 89.3 92.6 625.3
*P,0.05, **P,0.01 (two-tailed Student’s t test for comparison with the wild-type enzyme).
Fig. 6. Effects of F134C and R137 mutations on cPDF protein
expression in E. coli. (a) Western blot showing increased cPDF
expression in F134C ORF replacement bacteria and decreased
expression in R137S replacement. The bottom panel shows
Coomassie blue staining of total resolved proteins. (b) qPCR
detected similar amounts of cPDF mRNA among different
replacement E. coli strains. (c) qPCR detected a higher amount
of cPDF mRNA in the replacement E. coli carrying all mutations
found in the cPDF gene of Z1, as compared with the replacement
bacteria harbouring the 59-non-coding region and ORF of wild-
type C. trachomatis. Data in (a–c) are representative of three or
more experiments.
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transcription from the putative promoter region is also
detectable using a commercial E. coli RNAP holoenzyme
containing s
70,as
66 homologue with the capacity to
functionally substitute for the chlamydial primary s factor
in a number of cases examined (Hefty & Stephens, 2007;
Koehler et al., 1990; Shen et al., 2000; Tan et al., 1998).
Finally, the transcription was also evident with a hybrid
RNAP holoenzyme in which recombinant s
66 was used in
place of s
70.
Several lines of evidence indicate that the mutation in
GR10 causes resistance to PDF inhibitors by stabilizing the
interaction between the aCTD and DNA immediately
upstream of the 235 element of the cPDF promoter. First,
according to published work, the binding of the proximal
UP element by aCTD is centred at around nucleotide 241
(Chen et al., 2003; Ross et al., 1998), which coincides with
the mutation site in GR10. Furthermore, the CAA
mutation in GR10 is predicted to result in more efficient
aCTD binding because aCTD favours A+T-rich sequences
(Chen et al., 2003; Ross et al., 1998). Finally, the
transcription-enhancing activity of the GR10 mutation
became completely undetectable when the intact eRNAP
was replaced with DCTD.
Transcription analyses showed that, similar to the GR10
mutation, the Z1P235 mutation identified in the Z1
resistant variant has a stimulatory effect on cPDF gene
transcription. However, the GR10 and Z1P235 mutations
upregulate transcription by enhancing the interaction of
different components of the transcription machinery.
Whereas the Z1P235 mutation is predicted to result in a
more efficient 235 hexamer for s
66, the GR10 mutation
increases the interaction between the aCTD and the DNA
upstream of the 235 element. Previously, a number of
chlamydial promoters and their interactions with the
RNAP have been studied in vitro or with heterologous
systems (reviewed by Tan, 2007). However, to the best of
our knowledge, this study is the first one demonstrating
that single nucleotide changes in promoter elements can
affect drug susceptibility in Chlamydia.
Two other sites that affect GM6001 targeting efficiency are
found in the cPDF protein: F134 and R137. The abilities of
the F134C and R137S mutations to mediate resistance were
confirmed using a heterologous system. Accordingly,
replacement E. coli strains expressing either mutated
cPDF exhibit a higher level of GM6001 tolerance as
compared with bacteria expressing wild-type cPDF.
Interestingly, each of the mutations alone has no negative
effect on GM6001 binding; they contribute to resistance by
increasing the catalytic efficiency. The improved catalytic
efficiency in the R137S enzyme may be a key mechanism
for resistance in its replacement E. coli strain since the
protein is expressed less efficiently than wild-type enzyme.
In comparison, an increased stability of the F134C protein,
leading to a rise in the enzyme amount, is another
contributory factor. In both F134C and R137S mutants, the
elevations in Km along with the increases in kcat in the
absence of concurrent increases in Ki suggest that product
release and/or a conformational shift just prior to product
release may be largely rate-limiting in wild-type cPDF and
is accelerated in the mutant enzymes.
Compared with the F134C and R137S variants, the F134C/
R137S cPDF displayed an over sixfold increase in Ki over
wild-type and a nearly 10-fold elevation in Km. The
reduced affinity to GM6001 would confer resistance to the
inhibitor. Since there is also a 27% decrease in kcat/Km, the
large increase in Km suggests an extensive loss in substrate-
binding, which most probably has made the mutant cPDF
an ineffective enzyme in vivo. The fact that the F134C/
R137S ORF was not able to support E. coli growth until the
59 non-coding region carrying the Z1P235 and RBS
mutations were knocked-in concurrently to increase its
expression level supports this supposition. Finally, a
significantly larger increase in Km than that in Ki in the
F134C/R137S cPDF further supports the hypothesis that
product release and/or a conformational change before
product release is rate-limiting in cPDF, as noted above.
Recently, homology modelling has localized F134 and R137
in an a-helix that contributes to the formation of the
enzyme’s active site (Oey et al., 2011). Studies of PDFs from
other organisms using X-ray crystallography and NMR
spectroscopy have shown that binding of a ligand (i.e.
substrate, product or inhibitor) to the enzyme induces
conformational changes, particularly near the active site
(Amero et al., 2009; Guilloteau et al., 2002). Furthermore,
single amino acid substitutions proximal to the active site
canresultinchangesinstructureandligandbinding,leading
to resistance (see structures 3M6O, 3M6P, 3M6Q and 3M6R
at http://www.ncbi.nlm.nih.gov/structure). Similarly, our
enzymekineticdata suggestthat F134andR137also regulate
enzyme–ligand interactions and conformation during cata-
lysis. Thus, the F134C and R137S mutations each alone
reduce the affinity to the product, and in combination they
also decrease substrate- and inhibitor-binding.
In summary, the findings of a mutation in the cPDF gene as
the sole change in the GR10 genome as well as the
correlation of cPDF gene mutations with resistance
phenotype, cPDF gene expression and changes in kinetic
properties in the Z1 variant represent definitive evidence for
the targeting of cPDF by GM6001 in C. trachomatis.
Analyses of protein and mRNA expression in the chlamydial
variants, in vitro characterization of their promoters, kinetic
characterization of recombinant enzymes and studies using
the heterologous E. coli system indicate that the susceptibil-
ity of C. trachomatis to PDF inhibitors is controlled by cPDF
gene transcription, protein expression and stability as well as
catalytic properties of the cPDF enzyme. Since the Z1
mutant was obtained by random mutagenesis, it would not
be surprising if mutations in other loci of the genome
contribute to the resistant phenotype. Sequencing of the Z1
genome and characterization of additional mutated genes
may further advance the understanding of mechanisms
Regulation of chlamydial peptide deformylase
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to PDF inhibitors, although separating genes with true
regulatory functions from other mutated genes might prove
challenging.
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